# SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

> **NCT05764811** · NA · COMPLETED · sponsor: **National Cheng-Kung University Hospital** · enrollment: 40 (actual)

## Conditions studied

- Fatty Liver Disease

## Interventions

- **DRUG:** Canagliflozin 100mg

## Key facts

- **NCT ID:** NCT05764811
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-06
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764811, "SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05764811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*